Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Chemotherapy & Immunotherapy
Chemotherapy for uterine cancer
An in-depth guide to chemotherapy for uterine cancer, explaining how carboplatin and paclitaxel regimens destroy malignant cells, when systemic treatment is indicated after surgery or for advanced disease, how international prices in Turkey compare with the UK, US and Germany, what to expect across three-week treatment cycles, how side effects are managed, and how to verify hospital oncology standards.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Chemotherapy & Immunotherapy
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Chemotherapy for Uterine Cancer
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Chemotherapy for uterine cancer in Turkey: what it is and how it works
Chemotherapy for uterine cancer is a systemic treatment using cytotoxic drugs to destroy cancer cells or stop them from dividing. Unlike surgery or localised radiotherapy, chemotherapy circulates through the bloodstream to reach malignant cells that have spread beyond the womb. Uterine malignancies develop either in the inner lining as endometrial carcinomas or in the muscular wall as uterine sarcomas. Systemic therapy is vital when tumours invade deep into uterine muscle, involve lymph nodes, or recur after surgery.
Hospitals in Turkey deliver chemotherapy in dedicated medical oncology units led by multidisciplinary tumour boards. Depending on your diagnosis, treatment may be given after surgery to destroy microscopic residual cells (adjuvant therapy), before surgery to shrink tumours (neoadjuvant therapy), or to manage advanced disease. For wider cancer care options, see our guide to oncology treatments in Turkey.
Which drug regimens are used for uterine cancer?
The standard first-line protocol for endometrial cancer and uterine carcinosarcoma is carboplatin combined with paclitaxel. Carboplatin binds to cancer cell DNA to prevent replication, while paclitaxel disrupts cellular division during mitosis. Both medications are delivered intravenously on day one of a 21-day cycle, repeated for four to six cycles.
When tumours recur or when specific sarcomas are diagnosed, second-line options include doxorubicin, cisplatin, ifosfamide, gemcitabine, or docetaxel. Oncology teams also perform biomarker testing to determine whether conventional chemotherapy should be paired with molecular targeted therapies or immunotherapies.
Does chemotherapy for uterine cancer work and what does evidence show?
Extensive clinical trials, including the international PORTEC-3 and GOG-258 studies, confirm that adjuvant chemotherapy improves progression-free and overall survival in high-risk stage I, stage II, and stage III uterine cancers. In advanced stage IV or recurrent disease, combination chemotherapy achieves objective response rates of 40% to 60%, shrinking tumour deposits and alleviating symptoms.
However, chemotherapy cannot replace surgical hysterectomy and staging for resectable tumours. Furthermore, international guidelines from ESMO and ASCO do not recommend chemotherapy for low-risk stage I endometrioid cancer, where surgery alone provides high cure rates without cytotoxic exposure.
Chemotherapy for uterine cancer cost in Turkey compared with the UK, US and Germany
The table below outlines approximate cost ranges for chemotherapy courses across major countries. These figures reflect estimated hospital and medication fees rather than formal quotes, as every hospital calculates exact pricing from individual medical files.
| Country | Approximate cost per cycle | Approximate full course (6 cycles) |
|---|---|---|
| Turkey | €1,200 – €3,000 | €7,000 – €18,000 |
| United Kingdom | €3,500 – €7,500 | €20,000 – €45,000 |
| United States | €6,000 – €16,000 | €35,000 – €95,000 |
| Germany | €3,000 – €7,000 | €18,000 – €42,000 |
The overall chemotherapy for uterine cancer price varies based on drug dosages calculated by body surface area, port-a-cath insertion, baseline imaging, and supportive medications such as antiemetics and G-CSF injections. In Turkey, packages usually include oncologist consultations, day-unit infusion charges, routine pre-cycle blood tests, and airport transfers. Always request a written breakdown before confirming treatment.
Chemotherapy, immunotherapy or targeted therapy for uterine cancer?
Systemic treatment choices depend on tumour stage, histological subtype, and molecular biomarkers identified through pathology testing.
| Treatment type | Best suited to | Typical limits |
|---|---|---|
| Systemic chemotherapy (Carboplatin + Paclitaxel) | High-risk early stage (adjuvant), advanced stage III–IV, or recurrent uterine cancer regardless of biomarker status | Causes temporary systemic toxicity (myelosuppression, alopecia, neuropathy); requires recovery intervals between cycles |
| Immunotherapy (Checkpoint inhibitors e.g. Pembrolizumab, Dostarlimab) | Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) advanced or recurrent endometrial cancer | Ineffective as monotherapy in proficient (pMMR) tumours unless combined with targeted agents; carries immune-related adverse event risks |
| Targeted therapy (e.g. Tyrosine kinase inhibitors such as Lenvatinib) | Advanced or recurrent disease combined with immunotherapy, or specific molecular alterations (e.g. HER2 overexpression in serous carcinoma) | Requires specific genomic or molecular markers; potential cardiovascular and hypertensive side effects |
Modern clinical protocols frequently combine these approaches. Adding immunotherapy to first-line chemotherapy improves survival in advanced disease, while oral targeted therapy is combined with checkpoint inhibitors for mismatch repair proficient tumours.
Who is a candidate for uterine cancer chemotherapy, and who is not?
Suitability for systemic chemotherapy depends on FIGO stage, histological subtype, and general health. Good candidates include:
- Patients with stage III or IV endometrial cancer following debulking surgery.
- Patients with aggressive histological variants, including uterine serous carcinoma, clear cell carcinoma, or carcinosarcoma.
- Patients with stage I or II disease presenting high-risk features like deep myometrial invasion or extensive lymphovascular space invasion.
- Patients with recurrent disease after prior surgery or radiation.
- Individuals with adequate kidney, liver, and bone marrow function and an ECOG performance status of 0 to 2.
Chemotherapy is not recommended for low-risk stage IA grade 1–2 endometrioid cancer, where surgery alone provides high cure rates. Patients with severe renal impairment, unmanaged cardiac failure, severe neuropathy, or poor performance status (ECOG 3–4) are generally unsuitable because toxicities outweigh potential benefits.
How is chemotherapy administered: the treatment cycle step by step
Chemotherapy in Turkey is delivered as a structured outpatient or short inpatient procedure across scheduled 21-day cycles:
- Step 1: Clinical assessment and blood tests. Your oncologist reviews blood tests to verify that white blood cells, platelets, and kidney markers have recovered.
- Step 2: Vascular access. A port-a-cath or PICC line is placed under local anaesthesia to avoid vein damage from repeated injections.
- Step 3: Pre-medications. Intravenous dexamethasone, antihistamines, and antiemetics (such as ondansetron) are administered to prevent allergic reactions and nausea.
- Step 4: Drug infusion. Paclitaxel is infused over three hours under regular nursing observation, followed by carboplatin over 30 to 60 minutes.
- Step 5: Discharge and supportive care. After observation, you are discharged with take-home anti-nausea medications and care guidelines.
Chemotherapy for uterine cancer recovery and managing side effects
The chemotherapy for uterine cancer recovery timeline follows a three-week pattern between infusion sessions:
- Days 1–4 (Acute phase): Mild nausea, fatigue, and steroid wear-off are common. Rest, hydration, and prescribed antiemetics provide symptom relief.
- Days 5–10 (Nadir phase): White blood cell counts reach their lowest level, making infection risk highest. Monitor your temperature and report fever above 38°C immediately.
- Days 11–17 (Rebound phase): Bone marrow recovers and energy improves. Hair shedding typically begins around day 14 to 21.
- Days 18–21 (Pre-cycle recovery): Blood counts return to baseline levels in preparation for the next cycle.
For international chemotherapy for uterine cancer Turkey travel, patients typically stay five to seven days per cycle before returning home, or remain in Turkey for two consecutive cycles (four to five weeks) to complete care without frequent flights.
Assessing results: what scans and tumour markers show during treatment
In chemotherapy, treatment progress is evaluated using objective imaging scans and blood tests rather than visual before-and-after photographs. Doctors arrange contrast-enhanced CT, MRI, or PET-CT scans before treatment, mid-way through cycles (after cycle three), and four to six weeks following final treatment.
Radiologists apply RECIST criteria to measure whether tumours have disappeared completely (complete response), shrunk by at least 30% (partial response), or stabilised. Concurrently, blood levels of cancer antigen 125 (CA-125) are tracked to assess biochemical response. Although scans confirm anatomical reduction, completing all planned cycles remains essential to eliminate unseen microscopic tumour cells.
Risks, toxicities and long-term complications
Chemotherapy affects healthy dividing cells alongside cancer cells. Medical bodies, including the NHS, ESMO, and ASCO, document several recognised risks:
- Myelosuppression: Drops in white blood cells (neutropenia), red blood cells (anaemia), and platelets (thrombocytopenia), requiring infection precautions.
- Peripheral neuropathy: Paclitaxel may cause numbness, tingling, or pain in the hands and feet that can persist after treatment.
- Alopecia: Reversible hair loss across the scalp and body, typically starting two to three weeks after cycle one.
- Hypersensitivity reactions: Allergic responses during infusion, managed with premedication and slower infusion rates.
- Organ toxicities: Potential strain on renal function from carboplatin, alongside digestive side effects such as constipation or diarrhoea.
- Thromboembolism: Increased risk of deep vein thrombosis and pulmonary embolism during active malignancy and treatment.
Oncology teams monitor blood counts before each session and adjust dosages or delay cycles if significant toxicity arises.
How to choose an oncology centre in Turkey and questions to ask
When selecting a hospital in Turkey for cancer chemotherapy, look for the following quality standards:
- Multidisciplinary Tumour Board: Case reviews involving gynaecological surgical oncologists, medical oncologists, radiologists, and pathologists.
- International hospital accreditation: Licensing by the Turkish Ministry of Health and accreditation by bodies such as JCI (Joint Commission International).
- Comprehensive pathology and biomarker services: Laboratory facilities to review original biopsy slides and perform MMR, MSI, and HER2 profiling.
- Dedicated oncology units: Modern chemotherapy day wards staffed by certified oncology nurses with emergency resuscitation facilities.
Avoid centres that promise unrealistic cures, offer treatment without reviewing your biopsy specimens, lack intensive care support, or pressure you to pay before providing a medical protocol. Read how it works to understand patient planning, and submit your records via our free quote form.
Key questions to ask the oncology team:
- Will my treatment plan be reviewed by a gynaecological tumour board?
- What exact drug doses and infusion schedule are recommended for my condition?
- Does the quoted cost cover blood tests, port placement, and supportive medications?
- What emergency medical protocols exist if I develop a fever between cycles?
- How will infusion summaries and scan reports be shared with my doctor at home?
Hospitals with Oncology in Turkey
Frequently asked questions
Chemotherapy for uterine cancer is a systemic medical treatment using cytotoxic drugs to kill cancer cells or prevent them from multiplying. Administered intravenously through an infusion line or port, the drugs circulate throughout the body to treat endometrial cancer or uterine sarcoma that has invaded deep into the uterine muscle, spread to lymph nodes, or metastasised to distant organs.
Yes. Clinical evidence demonstrates that combination chemotherapy, primarily carboplatin and paclitaxel, significantly reduces recurrence in high-risk early-stage uterine cancer when given after surgery. In advanced or recurrent disease, it shrinks tumours, relieves clinical symptoms, and prolongs progression-free survival. However, responsiveness depends heavily on histological subtype, molecular classification, and disease stage.
In Turkey, chemotherapy for uterine cancer typically costs between €1,200 and €3,000 per single cycle, or approximately €7,000 to €18,000 for a standard six-cycle course. In contrast, equivalent regimens in the UK or Germany often range from €18,000 to €45,000. Final quotes depend on drug dosages, supportive premedications, and inpatient monitoring needs.
The international standard first-line regimen for both endometrial carcinoma and uterine carcinosarcoma is carboplatin combined with paclitaxel, given once every three weeks. Other medications that may be prescribed, particularly for recurrent disease or specific sarcomas, include doxorubicin, cisplatin, gemcitabine, docetaxel, and ifosfamide, selected according to pathology and prior treatment response.
Response is evaluated through regular CT, PET-CT, or MRI scans alongside blood markers such as CA-125. Scans illustrate whether existing tumours have shrunk, stabilised, or disappeared completely under standardised RECIST criteria. While imaging demonstrates anatomical reduction, microscopic residual cells may still require ongoing maintenance therapy or periodic surveillance to confirm lasting remission.
Chemotherapy is administered in cycles, typically three weeks apart. The first 3 to 5 days often involve acute fatigue and nausea, followed by a nadir in blood counts around days 7 to 14 when infection risk is highest. Most patients regain energy and normal blood counts by day 18 to 21, allowing the next cycle to proceed safely.
The intravenous infusion itself is not painful, though patients may feel slight coldness or aching at the cannulation or port site. The main physical discomfort arises from post-infusion side effects over subsequent days, including joint aching, fatigue, digestive upset, and peripheral neuropathy (numbness or tingling in extremities), which clinical teams manage using targeted supportive medications.
Chemotherapy kills rapidly dividing cells directly and works across most histological types. Immunotherapy enhances the body's own immune system to attack cancer and is particularly effective in tumours with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). Today, modern oncology protocols often combine both therapies in advanced stages for enhanced disease control.
The most significant risks include myelosuppression (reduced white blood cells, red cells, and platelets leading to infection, anaemia, or bleeding), peripheral neuropathy from paclitaxel, temporary hair loss, fatigue, kidney strain from carboplatin, and allergic infusion reactions. Oncology teams monitor blood counts before every session and adjust doses promptly if significant toxicities appear.
For each cycle, international patients typically arrive 1 to 2 days before infusion for oncology consultation and blood tests, receive the infusion as an outpatient or overnight stay, and remain for 3 to 5 days of observation before flying home. Alternatively, some patients complete two back-to-back cycles across four to five weeks in Turkey.
Patient stories